Sotorasib Is a Pan-RASG12C Inhibitor Capable of Driving Clinical Response in NRASG12C Cancers.
Douglas A RubinsonNoritaka TanakaFerran Fece de la CruzKevin S KapnerMichael H RosenthalBryanna L NordenHaley BarnesSara EhnstromAlvin A Morales-GironLauren K BraisChristopher T LemkeAndrew J AguirreRyan B CorcoranPublished in: Cancer discovery (2024)
These studies demonstrate that certain KRASG12C inhibitors effectively target all RASG12C mutations and that sotorasib specifically is a potent NRASG12C inhibitor capable of driving clinical responses. These findings have important implications for the treatment of patients with NRASG12C or HRASG12C cancers and could guide design of NRAS or HRAS inhibitors. See related commentary by Seale and Misale, p. 698. This article is featured in Selected Articles from This Issue, p. 695.